Resmetirom-mediated reduction in hepatic fat.
Least squares (LS) mean change from baseline (95% confidence interval (CI)) in hepatic fat (measured by magnetic resonance imaging-proton density fat fraction (MRI-PDFF)) at Week 52 in patient subgroups of the double-blind 100 mg resmetirom and double-blind 80 mg resmetirom arms. Marker shows median. High SHBG, population with ≥120% increase from baseline in SHBG.
